All News
Abatacept in pts at risk of #RA data from clinical trial.
213 pts, 31 centers.
Pts with multiple autoantibodies improved the most with abatacept.
@rheumnow #EULAR2023 https://t.co/c82jx0cAEq
Bella Mehta bella_mehta ( View Tweet)
Central sensitization of neuropathic pain in #PsA - patient reported outcomes.
114 pts. And 22 percent with fibromyalgia
Pts with neuropathic pain didnt reach low disease activity or remission.
@RheumNow #EULAR2023 highlights! https://t.co/Gxkcrruamp
Bella Mehta bella_mehta ( View Tweet)
MmF and Tacrolimus both work in systemic sclerosis with ILD. @RheumNow #EULAR2023 https://t.co/Ro6AjP3nij
Bella Mehta bella_mehta ( View Tweet)
2023 update @EULAR recommendations imaging in GCA
What's new:
1. US = first line imaging test
2. Axillary arteries should be included in standard examination
3. Alternative imaging FDG-PET or MRI
4. Takayasu: MRI preferred CT or FDG-PET alternatives
@Rheumnow #EULAR23 LB0008 https://t.co/rGPfOPX1gI
Aurelie Najm AurelieRheumo ( View Tweet)
CAR-T cells in refarctory SLE- long term data presented #EULAR2023
Pts did well except some mild cytopenias. Pts remained in remission.
Maybe a good option in the near future for refractory pts!
@RheumNow https://t.co/NWoFBipOiQ
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 Clinical Highlights. CTD: OP0240 Open label study (N=26) showed stabilisation/improvement in FVC in patients with #ILD treated either Tacrolimus vs MMF. No efficacy difference between both therapies @RheumNow https://t.co/d3rCzNgYHK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Microvascular visualization in Behcet's disease by ultrasound. Maybe really useful in cases which are difficult to diagnose and may not need biopsies in some pts.
#EULAR2023 @RheumNow https://t.co/PbC3tCe7v6
Bella Mehta bella_mehta ( View Tweet)
Denosumab in hand OA prevented erosions!
#eular2023 @RheumNow https://t.co/Ij2CVjh1ET
Bella Mehta bella_mehta ( View Tweet)
New treatment target for #gout
#EULAR2023
SEL-212 - 2 drugs one after the other!
- tolerogenic nanoparticles containing rapamycin followed by pegadricase
-only 50% reponded, but there were pts who didn't respond at all.
@RheumNow https://t.co/RXK58piU85
Bella Mehta bella_mehta ( View Tweet)
Treat early it is also cheaper!
5 yr cost of RA ttmt
€11250 ACPA+ > €3526 ACPA-
bDMARDS users
€44788 ACPA+ > €40896 ACPA-
ACPA- "late" ttmt 46% more expensive
ACPA+ early vs. late = similar costs
@Rheumnow #EULAR23 POS0369 https://t.co/dg9T9fqJDl
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 Clinical Highlights. Vasculitis: OP0061 - new US imaging showing vessel inflammation differentiating patients with Behcet’s vs No-BD. OP0304: cohort study showed Benralizumab (IL5 RA) given for eosinophilic asthma also improved BVAS. RCT for EGPA is ongoing @RheumNow https://t.co/7uohfjGk49
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs.
OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE?
DANBIO study (>1,300 pts w/ IA)
Costs similar or decreased 9 mo after mandatory switching to ADA biosimilar (GP2017 or SB5)
Decrease 15% GP2017 switchers
#EULAR23 POS0376 @RheumNow https://t.co/bAeqYhNgf0
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nocicpetor ablation in mice model with #OA - pain was reduced.
If its done before OA progression, it helps, but after it doesnt!
@AM_Malf work highligted at #EULAR2023 @RheumNow https://t.co/zvxHmlCIrD
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #LB0005 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a)feasible to use ultrasound & clinical as endpoints, b)new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/kGDZ6EqLtq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2023 recommendation update summary from the 2018 in #PsA whats new!
- 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline)
- safety now to to considered!
- consider the full picture - extraarticular manifestations
@rheumnow https://t.co/7GBILtCX4i
Bella Mehta bella_mehta ( View Tweet)
meds for PsA at #EULAR2023 recommendations
bDMARD after csDMARD (no order proposed)
@RheumNow https://t.co/bHMG4A8nmP
Bella Mehta bella_mehta ( View Tweet)
I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324 @RheumNow Small differences but maybe a script to go south is the right Rx! https://t.co/tjd6FjEHij
Janet Pope Janetbirdope ( View Tweet)